The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...

Cancer survivors may experience anxiety over minor illnesses, fearing recurrence despite being in remission. The "positivity trap" can make survivors feel invalidated, as constant reassurance may ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses the growing view that follicular lymphoma could be viewed as ...

Monjuvi, combined with Rituxan and Revlimid, extends progression-free survival to 22 months, reducing disease progression risk by over 50%. The inMIND trial's design and diverse patient population ...

"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...

DIAMOND BAR, Calif., Aug. 13, 2025 /PRNewswire/ -- CIT Therapeutics, Inc. (CIT), a biotechnology company focused on developing next-generation small molecule therapies targeting SUMOylation for cancer ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Epcoritamab monotherapy achieved high overall (84.6%) and complete response rates (67.1%) in relapsed/refractory follicular lymphoma patients with multiple prior therapies. Combination therapy with ...